Introduction: Who Should Undergo Diagnostics

Anyone who notices a new or changing spot on their skin should consider seeking diagnostic evaluation. Superficial spreading melanoma can appear anywhere on the body, though it most commonly develops on the trunk in men (particularly the upper back) and on the legs in women^[2]. About 70% of these melanomas develop on skin that previously appeared completely normal, while roughly 25% arise from an existing mole^[2][12].

People at higher risk should be especially vigilant and seek regular skin examinations. High-risk individuals include those with very fair skin that burns easily, particularly people with skin types 1 and 2^[2]. If you have more than five unusual-looking moles (also called atypical naevi or dysplastic naevi, which are moles that look different from typical moles), you face increased risk^[2]. A strong family history also matters—having two or more first-degree relatives (parents, siblings, or children) with melanoma significantly raises your risk^[2].

Other important risk factors include a history of blistering sunburns, especially during childhood or adolescence, and frequent exposure to ultraviolet radiation from either natural sunlight or artificial sources like tanning beds^[2][5]. People with blue or green eyes, red or blond hair, and those who work indoors but recreate outdoors also show somewhat elevated risk^[2].

It’s advisable to see a healthcare provider if you observe changes in an existing mole or the development of a new skin lesion, especially if it shows signs of evolution over time. Superficial spreading melanoma typically grows slowly over months to years, but some can change more rapidly over weeks or months^[12][14]. Only about 15% of melanomas occur before age 40, and they are rare under age 20, though they can affect people of all ages^[2][12].

Diagnostic Methods for Identifying Superficial Spreading Melanoma

Visual Examination and the ABCDE Rule

The first step in diagnosing superficial spreading melanoma is a thorough visual examination by a healthcare professional, typically a dermatologist (a doctor who specializes in skin conditions). During this examination, the doctor will carefully inspect any suspicious spots or lesions on your skin^[11].

Healthcare professionals often use a memory tool called the ABCDE rule to evaluate potentially problematic skin lesions. This acronym helps identify warning signs that a spot may be melanoma rather than a harmless mole^[3][5]:

• A for Asymmetry: One half of the mole or spot does not match the other half in shape or appearance
• B for Border: The edges are irregular, ragged, notched, or poorly defined rather than smooth
• C for Color: The color is not uniform throughout and may include different shades of brown, black, tan, red, white, or blue
• D for Diameter: The spot measures larger than 6 millimeters across (about the size of a pencil eraser), though melanomas can sometimes be smaller
• E for Evolving: The spot is new or has changed in size, shape, or color over time

Superficial spreading melanoma can present as a slowly growing or changing flat patch of discolored skin. At first, it may look like an ordinary mole, freckle, or age spot, but it becomes more distinctive over time^[2][12]. The lesion often has an irregular shape with jagged borders and shows multiple colors^[4]. It can be either flat or slightly raised from the skin surface^[4][14].

Some additional features that may indicate superficial spreading melanoma include itching (though not all melanomas itch), and the lesion appearing different from other spots on your body^[2][5]. The average size at diagnosis is typically around 20 millimeters (about three-quarters of an inch) across^[14][20].

Skin Biopsy: The Definitive Diagnostic Test

If a healthcare provider suspects melanoma based on visual examination, the next step is a biopsy, which involves removing a sample of the suspicious skin tissue for laboratory testing. This is the only way to definitively diagnose melanoma^[11].

Different types of biopsy procedures can be performed depending on the size and location of the suspicious lesion. One common approach is a punch biopsy, which uses a round-tipped cutting tool to remove deeper layers of skin along with some surrounding tissue^[11]. The tool is pressed into the skin around the suspicious area, creating a cylindrical sample. Depending on the size of the sample removed, stitches may be needed to close the wound afterward.

Another technique is called an excisional biopsy. During this procedure, a scalpel is used to cut out the entire lesion or lump along with a margin of healthy skin around it^[11]. Stitches are typically required to close the wound after an excisional biopsy. Healthcare professionals generally recommend removing the entire suspicious growth when possible, which is why excisional biopsy is often preferred for suspected melanomas.

After the tissue sample is removed, it is sent to a laboratory where a specialist called a pathologist examines it under a microscope. The pathologist looks for the presence of malignant (cancerous) melanocytes (pigment cells) and evaluates various characteristics of the cells^[2][12]. They will determine whether the cells are confined to the outermost layer of skin (the epidermis) or have invaded deeper layers.

Determining Thickness and Staging

If the biopsy confirms melanoma, the next crucial step is determining how thick the melanoma is and whether it has spread. The thickness of the melanoma is one of the most important factors in predicting prognosis and determining the best treatment approach^[11].

Pathologists measure melanoma thickness by examining the tissue sample under a microscope. In general, the thicker the melanoma, the more serious the disease^[11]. Superficial spreading melanoma begins by growing horizontally along the surface of the skin—this is called the radial growth phase. During this phase, the malignant cells tend to stay within the epidermis for a prolonged period, sometimes for months to years or even decades^[2][12].

Eventually, an unknown proportion of superficial spreading melanomas become invasive, meaning the cancer cells cross the boundary (called the basement membrane) between the epidermis and the deeper layer of skin called the dermis^[2][12]. At this point, the melanoma can grow more rapidly and penetrate deeply into the skin. When this happens, it’s often because a rapidly-growing nodular melanoma has arisen within the superficial spreading melanoma^[2][12].

Additional Tests to Check for Spread

If the melanoma has grown beyond a certain thickness or shows other concerning features, your healthcare team may recommend additional tests to determine whether the cancer has spread to other parts of the body. These staging tests help doctors create the most appropriate treatment plan.

One important test involves checking nearby lymph nodes, which are small bean-shaped structures that are part of your immune system. If melanoma cells have spread, they often first travel to the nearest lymph nodes. Your doctor may examine and feel the lymph nodes near the melanoma site during a physical examination to check if they are swollen^[11].

In some cases, surgery may be needed to remove swollen lymph nodes or to check if the cancer has spread to them^[2]. Other tests that might be ordered for more advanced melanomas include imaging studies such as CT scans, MRI scans, or PET scans to look for cancer in other organs^[11].

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or approaches to managing melanoma. If you’re considering participating in a clinical trial, you will typically need to undergo specific tests to determine whether you qualify for the study. These qualification criteria, called eligibility criteria, help ensure that the trial enrolls patients who are most likely to benefit from or provide useful information about the treatment being studied.

Standard diagnostic tests for clinical trial qualification typically include confirmation of the melanoma diagnosis through biopsy and pathological examination. The pathology report must document that you have melanoma and provide detailed information about the tumor characteristics^[12].

Staging tests are almost always required for clinical trial enrollment. These help determine the extent of your disease and whether it fits the stage of melanoma that the trial is studying. For superficial spreading melanoma, staging involves determining the thickness of the tumor and whether it has spread to lymph nodes or other parts of the body^[11].

Some clinical trials may require testing for specific genetic mutations within the melanoma cells. For example, many superficial spreading melanomas have a particular gene mutation called BRAFV600E^[2][12]. A sample of the melanoma tissue is tested in a laboratory to check for the presence of this and other genetic changes. This testing helps doctors determine whether you might respond to certain targeted therapies being studied in clinical trials.

Blood tests are commonly required before entering a clinical trial. These tests check your overall health and organ function, including your liver, kidneys, and bone marrow. The results help ensure that you’re healthy enough to tolerate the experimental treatment and that the treatment is safe for you.

Imaging tests such as CT scans, MRI scans, or PET scans may be required to establish a baseline measurement of your melanoma before treatment begins. These scans create detailed pictures of the inside of your body and can detect whether melanoma has spread to organs like the lungs, liver, brain, or bones. Having baseline scans allows researchers to compare later scans to see whether the treatment is working.

Performance status assessments are often part of clinical trial qualification. Your healthcare team will evaluate how well you can perform everyday activities and take care of yourself. This helps determine whether you’re strong enough to participate in the trial and tolerate potential side effects from the experimental treatment.

Additional specialized tests may be required depending on the specific clinical trial. Some trials studying immunotherapy treatments (which help your immune system fight cancer) may require tests to evaluate your immune system function. Others might need tissue samples for research purposes beyond standard diagnosis, which are collected during the biopsy or surgical procedures you’ve already undergone.